细胞因子和生长因子的发展史

IF 2.2 4区医学 Q3 HEMATOLOGY

Best Practice & Research Clinical Haematology Pub Date : 2025-03-01 DOI:10.1016/j.beha.2025.101612

Smith Kungwankiattichai , Richard T. Maziarz

{"title":"细胞因子和生长因子的发展史","authors":"Smith Kungwankiattichai , Richard T. Maziarz","doi":"10.1016/j.beha.2025.101612","DOIUrl":null,"url":null,"abstract":"<div><div>The discovery and development of cytokines and growth factors represent transformative events in modern medicine, spanning from early observations of immune mediators to current therapeutic applications. This review chronicles the historical progression from the initial identification of permeability factors in 1926 to contemporary engineered cytokine therapeutics. Key milestones include the discovery of interferon (1957), the characterization of colony-stimulating factors, and the development of recombinant proteins in the 1980s. The field has evolved from basic understanding of immune communication to sophisticated therapeutic interventions, including targeted inhibitors and engineered cell therapies. While significant advances have been made in treating various diseases through cytokine modulation, challenges remain in managing pleiotropic effects and optimizing delivery systems. Recent innovations in bioengineering and cell therapy suggest promising directions for future therapeutic applications.</div></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"38 1","pages":"Article 101612"},"PeriodicalIF":2.2000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The history of cytokines and growth factors development\",\"authors\":\"Smith Kungwankiattichai , Richard T. Maziarz\",\"doi\":\"10.1016/j.beha.2025.101612\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>The discovery and development of cytokines and growth factors represent transformative events in modern medicine, spanning from early observations of immune mediators to current therapeutic applications. This review chronicles the historical progression from the initial identification of permeability factors in 1926 to contemporary engineered cytokine therapeutics. Key milestones include the discovery of interferon (1957), the characterization of colony-stimulating factors, and the development of recombinant proteins in the 1980s. The field has evolved from basic understanding of immune communication to sophisticated therapeutic interventions, including targeted inhibitors and engineered cell therapies. While significant advances have been made in treating various diseases through cytokine modulation, challenges remain in managing pleiotropic effects and optimizing delivery systems. Recent innovations in bioengineering and cell therapy suggest promising directions for future therapeutic applications.</div></div>\",\"PeriodicalId\":8744,\"journal\":{\"name\":\"Best Practice & Research Clinical Haematology\",\"volume\":\"38 1\",\"pages\":\"Article 101612\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Best Practice & Research Clinical Haematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1521692625000179\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Best Practice & Research Clinical Haematology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1521692625000179","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

细胞因子和生长因子的发现和发展代表了现代医学的变革性事件，从免疫介质的早期观察到目前的治疗应用。本文回顾了从1926年渗透性因子的初步鉴定到当代工程化细胞因子治疗的历史进展。关键的里程碑包括干扰素的发现（1957年）、集落刺激因子的表征以及20世纪80年代重组蛋白的发展。该领域已经从对免疫通讯的基本理解发展到复杂的治疗干预，包括靶向抑制剂和工程细胞疗法。虽然在通过细胞因子调节治疗各种疾病方面取得了重大进展，但在管理多效性效应和优化给药系统方面仍然存在挑战。最近在生物工程和细胞治疗方面的创新为未来的治疗应用提供了有希望的方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The history of cytokines and growth factors development

The discovery and development of cytokines and growth factors represent transformative events in modern medicine, spanning from early observations of immune mediators to current therapeutic applications. This review chronicles the historical progression from the initial identification of permeability factors in 1926 to contemporary engineered cytokine therapeutics. Key milestones include the discovery of interferon (1957), the characterization of colony-stimulating factors, and the development of recombinant proteins in the 1980s. The field has evolved from basic understanding of immune communication to sophisticated therapeutic interventions, including targeted inhibitors and engineered cell therapies. While significant advances have been made in treating various diseases through cytokine modulation, challenges remain in managing pleiotropic effects and optimizing delivery systems. Recent innovations in bioengineering and cell therapy suggest promising directions for future therapeutic applications.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Best Practice & Research Clinical Haematology 医学-血液学

CiteScore

4.20

自引率

0.00%

发文量

审稿时长

35 days

期刊介绍： Best Practice & Research Clinical Haematology publishes review articles integrating the results from the latest original research articles into practical, evidence-based review articles. These articles seek to address the key clinical issues of diagnosis, treatment and patient management. Each issue follows a problem-orientated approach which focuses on the key questions to be addressed, clearly defining what is known and not known, covering the spectrum of clinical and laboratory haematological practice and research. Although most reviews are invited, the Editor welcomes suggestions from potential authors.